Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Pelt – page 71

870 clinical trials in Pelt, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Pelt at a glance
870
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

870 trials in Pelt

Open in trial search

Ischaemic stroke

Not recruiting

Study on the Safety and Effectiveness of Tenecteplase for Patients with Acute Ischemic Stroke and Incomplete Reperfusion After Mechanical Thrombectomy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tenecteplase
  • Sponsor:Insel Gruppe AG

Study on JNJ-81201887 for Treating Geographic Atrophy in Age-related Macular Degeneration Patients

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Onzemipgene parvec
  • Sponsor:Janssen Cilag International

Malignant melanoma

Not recruiting

Study Comparing MK-7684A (Vibostolimab and Pembrolizumab) with Pembrolizumab for Adults and Children with High-Risk Stage II-IV Melanoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing Darolutamide and Androgen Deprivation Therapy to Placebo and Androgen Deprivation Therapy in Men with High-Risk Prostate Cancer Recurrence

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Bayer AG

Study on Radiotherapy with Xevinapant or Placebo for Older Patients with Advanced Head and Neck Cancer

Investigational
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:Xevinapant
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Study on Luspatercept and Epoetin Alfa for Treating Anemia in Patients with Low to Intermediate Risk Myelodysplastic Syndromes Needing Blood Transfusions

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Epoetin Alfa
  • Sponsor:Celgene Corp.

Study on Milvexian and Drug Combination for Patients Recovering from a Heart Attack

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Janssen Cilag International

Study on Rifaximin for Delaying Hepatic Encephalopathy in Cirrhosis Patients

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Rifaximin
  • Sponsor:Salix Pharmaceuticals Inc.

Study on Valaciclovir to Prevent Congenital CMV Infection in Pregnant Women with First Trimester CMV Infections

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Valaciclovir
  • Sponsor:UZ Leuven

Study of MK-7684A, Etoposide, and Platinum Drugs for Patients with Extensive-Stage Small Cell Lung Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing Axicabtagene Ciloleucel and Standard Treatment for Adults with High-Risk Large B-Cell Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Kite Pharma Inc.

Study of Belrestotug and Dostarlimab for Patients with Untreated Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Pelt

What the registry says about research in the country

01 Multiple Sclerosis Research

Extensive research focusing on relapsing forms of multiple sclerosis, evaluating novel therapeutic approaches and comparing treatment efficacies. Studies investigate various medications including frexalimab and remibrutinib against established treatments.

  • Relapsing MS Therapies
  • Disease Progression Analysis
  • Treatment Comparison Studies

Several trials aim to assess reduction in relapse frequency and improvement in patient outcomes.

02 Progressive MS Studies

Dedicated research into primary progressive multiple sclerosis (PPMS) and secondary progressive forms, exploring innovative treatments and their impact on disease progression. Studies evaluate higher-dose protocols and long-term effectiveness.

  • Disability Progression Markers
  • Novel Treatment Approaches
  • Long-term Safety Assessments

Focus on developing treatments to delay disability progression and improve patient mobility.

03 Advanced Therapeutic Studies

Investigation of innovative treatment modalities including BTK inhibitors and combination therapies. Research includes assessment of brain remyelination and neurodegeneration markers.

  • Biomarker Analysis
  • Pharmacokinetic Studies
  • Safety Monitoring

Comprehensive evaluation of new therapeutic approaches using advanced imaging and clinical assessments.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.